Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy

Virchows Archiv

Volumn 459, Issue 2, 2011, Pages 183-191

  Bösmüller, Hans ^a,b   Haitchi Petnehazy, Sophie ^a   Webersinke, Gerald ^a   Marschon, Renate ^a   Roithmeier, Franz ^a   Stummvoll, Wolfgang ^a   Fehm, Tanja ^b   Klier Richter, Margit ^b   Bonzheim, Irina ^b   Staebler, Annette ^b   Fend, Falko ^b  

^a Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

ERCC1 immunohistochemistry; ERCC1 mRNA expression; ERCC1 SNP; Intraepithelial lymphocytes; Serous ovarian adenocarcinoma; Stromal lymphocytes

Indexed keywords

CARBOPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYSTADENOCARCINOMA, SEROUS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 80052392759     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-011-1110-1     Document Type: Article

References (37)

1. SH Jeong JH Jung JH Han JH Kim YW Choi HW Lee SY Kang YH Hwang Ms Ahn OHYT Choi JH M Chun S Kang KJ Park SC Hwang SS Sheen 2009 Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy Lung Cancer 65 377 382 19150580 10.1016/j.lungcan.2008.12.005
2. KA Olaussen A Dunant P Fouret E Brambilla F André V Haddad E Taranchon M Filipits R Pirker HH Popper R Stahel L Sabatier JP Pignon T Tursz T Le Chevalier JC Soria IALT Bio Investigators 2006 DNA repair by ERCC1 in non-small lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 983 991 16957145 10.1056/NEJMoa060570 1:CAS:528:DC%2BD28XpsFKmtLw%3D (Pubitemid 44343542)
3. A Vilmar JB Sorensen 2009 Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatmend of non-small cell lung cancer with spezial emphasis on carboplatin: a review of current literature Lung Cancer 64 131 139 18804893 10.1016/j.lungcan.2008.08.006
4. KM Darcy C Tian E Reed 2007 A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy Cancer Res 67 4474 4481 17483363 10.1158/0008-5472.CAN-06-4076 1:CAS:528:DC%2BD2sXltVyrtro%3D (Pubitemid 46815098)
5. S Kang W Ju JW Kim NH Park YS Song SC Kim SY Park SB Kang HP Lee 2006 Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer Exp Mol Med 38 320 324 16819291 1:CAS:528:DC%2BD28XmvFyitLs%3D (Pubitemid 44033245)
6. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA, Gynecologic Oncology Group Phase III Trial 2008 Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer J Clin Oncol 26 3598 3606 10.1200/JCO.2008.16.1323
7. S Smith D Su IA Rigault de la Longrais P Schwartz M Puopolo TJ Rutherford G Mor H Yu D Katsaros 2007 ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy J Clin Oncol 25 5172 5179 18024864 10.1200/JCO.2007.11.8547 1:CAS:528:DC%2BD2sXhsVKnsb%2FF (Pubitemid 350232247)
8. KD Steffensen M Waldstrom A Jakobson 2009 The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer Int J Gynecol Cancer 19 820 825 19574766 10.1111/IGC.0b013e3181a12e09
9. R Altaha X Liang JJ Yu E Reed 2004 Excision repair cross complementing-group. Gene expression and platinum resistance Int J Mol Med 14 959 970 15547660 1:CAS:528:DC%2BD2MXhsVymuw%3D%3D
10. M Dabholkar J Vionnet F Bostick-Bruton JJ Yu E Reed 1994 Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy J Clin Invest 94 703 708 8040325 10.1172/JCI117388 1:CAS:528:DyaK2cXlsVymsrg%3D (Pubitemid 24251002)
11. J Weberpals K Garbuio A O'Brian K Clark-Knowles S Doucette O Antoniuk G Goss J Dimitroulakos 2009 The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer Int J Cancer 124 806 815 19035454 10.1002/ijc.23987 1:CAS:528:DC%2BD1MXhvVShsro%3D
12. J Bellmunt L Paz-Ares M Cuello FL Cecere S Albiol V Guillem E Gallardo J Carles P Mendez JJ de la Cruz M Taron R Rosell J Baselga 2007 Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy Ann Oncol 18 522 528 17229776 10.1093/annonc/mdl435 1:STN:280:DC%2BD2s7hsFKqtg%3D%3D (Pubitemid 46359633)
13. M Selvakumaran DA Pisarcik R Bao AT Yeung TC Hamilton 2003 Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Res 63 1311 1316 12649192 1:CAS:528: DC%2BD3sXit1Sgtbs%3D (Pubitemid 36348710)
14. JI Weberpals KV Clark-Knowles BC Vanderhyden 2008 Sporadic epithelial ovarian cancer Clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway J Clin Oncol 26 3259 3267 18591560 10.1200/JCO.2007.11.3902 1:CAS:528:DC%2BD1cXptlKgur4%3D
15. KD Steffensen M Waldstrom U Jeppesen I Brandslund A Jakobson 2008 Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer Int J Gynecol Cancer 18 702 710 17961161 10.1111/j.1525-1438.2007.01068.x 1:STN:280:DC%2BD1crisl2ltQ%3D%3D (Pubitemid 352020157)
16. JJ Yu KB Lee C Mu Q Li TV Abernathy F Bostick-Bruton E Reed 2000 Comparison of two ovarian carcinoma cell lines (A2780/CP70 an MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene Int J Oncol 16 555 560 10675489 1:CAS:528:DC%2BD3cXhsF2murg%3D
17. SF Adams DA Levine MG Cadungog R Hammond A Facciabene N Olvera SC Rubin J Boyd PA Gimotty G Coukos 2009 Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer Cancer 115 2891 2902 19472394 10.1002/cncr.24317
18. B Clarke AV Tinker CH Lee S Subramanian M van de Rijn D Turbin S Kalloger G Han K Ceballos MG Cadungog DG Huntsman G Coukos CB Gilks 2009 Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss Mod Pathol 22 393 402 19060844 10.1038/modpathol. 2008.191 1:CAS:528:DC%2BD1MXisVSntLg%3D
19. S Kondratiev E Sabo E Yakirevich O Lavie MB Resnick 2004 Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma Clin Cancer Res 10 4450 4456 15240536 10.1158/1078-0432.CCR-0732-3 (Pubitemid 38878888)
20. E Sato SH Olson J Ahn B Bundy H Nishikawa F Qian AA Jungbluth D Frosina S Gnjatic C Ambrosone J Kepner T Odunsi G Ritter S Lele YT Chen H Ohtani LJ Old K Odunsi 2005 Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc Natl Acad Sci USA 102 18538 18543 16344461 10.1073/pnas.0509182102 1:CAS:528:DC%2BD28Xpt1Om (Pubitemid 43011261)
21. H Tel-A AE Alla MA Laban RM Fahmy 2004 Immunophenotyping of tumor-infiltrating mononuclear cells in ovarian carcinoma Pathol Oncol Res 10 80 84 10.1007/BF02893460 (Pubitemid 38915599)
22. MS Thompson SC Mok 2009 Immunopathogenesis of ovarian cancer Minerva Med 100 357 370 19910889 1:STN:280:DC%2BD1MjlvFyhtQ%3D%3D
23. JR Webb DA Wick JS Nielsen E Tran K Milne E McMurtrie BH Nelson 2010 Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer Gynecol Oncol 118 228 236 20541243 10.1016/j.ygyno.2010.05.016 1:CAS:528: DC%2BC3cXpvFWlt7w%3D
24. T Yang EM Wall K Milne P Theiss P Watson BH Nelson 2007 CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism Clin Cancer Res 13 7172 7180 18056198 10.1158/1078-0432.CCR-07-1724 1:CAS:528:DC%2BD2sXhtlyitLvM (Pubitemid 350276904)
25. MR Raspollini F Castiglione D Rossi Degl'innocenti G Amunni A Villanucci F Garbini G Baroni GL Taddei 2005 Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma Ann Oncol 16 590 596 15699022 10.1093/annonc/mdi112 1:STN:280:DC%2BD2M7kvVWmsg%3D%3D (Pubitemid 40613325)
26. M Stumpf A Hasenburg MO Riener U Jütting C Wang Y Shen M Orlowska-Volk P Fisch Z Wang G Gitsch M Werner S Lassmann 2009 Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes Br J Cancer 101 1513 1521 19861998 10.1038/sj.bjc.6605274 1:STN:280:DC%2BD1MjitVKjsA%3D%3D
27. K Specht M Kremer U Müller S Dirnhofer M Rosemann H Höfler L Quintanilla-Martinez F Fend 2002 Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections Clin Cancer Res 8 2902 2911 12231535 1:CAS:528: DC%2BD38XnvVWitr4%3D (Pubitemid 35025738)
28. S Scheil-Bertram P Tylus-Schaaf A du Bois P Harter M Oppitz N Ewald-Riegler A Fisseler-Eckhoff 2010 Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma Gynecol Oncol 119 325 331 20728204 10.1016/j.ygyno.2010.07.018 1:CAS:528:DC%2BC3cXht1KqsrfI
29. TC Krivak KM Darcy C Tian M Bookman H Gallion CB Ambrosone JA Deloia 2011 Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; A Gynecologic Oncology Group Study Gynecol Oncol 122 121 126 21496891 10.1016/j.ygyno.2011.03.027 1:CAS:528:DC%2BC3MXmslOnsLw%3D
30. NR Bhagwat VY Roginskaya MB Acquafondata R Dhir RD Wood LJ Niedernhofer 2009 Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue Cancer Res 69 6831 6838 19723666 10.1158/0008-5472.CAN-09-1237 1:CAS:528: DC%2BD1MXhtVOmt7fL
31. K Specht E Haralambieva K Bink M Kremer S Mandl-Weber I Koch R Tomer H Hofler E Schuuring PM Kluin F Fend L Quintanilla-Martinez 2004 Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels Blood 104 1120 1126 15090460 10.1182/blood-2003-11-3837 1:CAS:528: DC%2BD2cXmslKgsLk%3D (Pubitemid 39038033)
32. L Martinet R Poupot P Mirshahi A Rafii JJ Fournié M Mirshahi M Poupot 2010 Hospicells derived from ovarian cancers stroma inhibit T-cell immune responses Int J Cancer 126 2143 2152 19739080 1:CAS:528:DC%2BC3cXisFemtbo%3D
33. M Tomsová B Melichar I Sedláková I Steiner 2008 Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma Gynecol Oncol 108 415 420 18037158 10.1016/j.ygyno.2007.10.016 (Pubitemid 351174290)
34. K Milne M Köbel SE Kalloger RO Barnes D Gao CB Gilks PH Watson BH Nelson 2009 Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors PLoS One 4 e6412 19641607 10.1371/journal.pone.0006412
35. A Al-Attar M Shehata L Durrant P Moseley S Deen S Chan 2010 T cell density and location can influence the prognosis of ovarian cancer Pathol Oncol Res 16 361 370 20024633 10.1007/s12253-009-9230-5
36. JC Barnett SM Bean RS Whitaker E Kondoh T Baba S Fujii JR Marks HK Dressman SK Murphy A Berchuck 2010 Ovarian cancer tumor infiltrating T-regulatory (Treg) cells are associated with a metastatic phenotype Gynecol Oncol 116 556 562 20006900 10.1016/j.ygyno.2009.11.020 1:CAS:528: DC%2BC3cXhs1arurk%3D
37. D Wolf AM Wolf H Rumpold H Fiegl AG Zeimet E Muller-Holzner M Deibl G Gastl E Gunsilius C Marth 2005 The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer Clin Cancer Res 11 8326 8331 16322292 10.1158/1078-0432.CCR-05- 1244 1:CAS:528:DC%2BD2MXht1KjsrnM (Pubitemid 41746944)